In the literature: August 2018

by Juan-Miguel Cejalvo, Gema Bruixola, Federica Papaccio
Published 2019-07-01

In the literature: June 2020

by Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes, Desamparados Roda
Published 2020-10-01

In the literature: April 2019

by Gema Bruxiola, Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes
Published 2019-04-01

In the literature: June 2019

by Juan-Miguel Cejalvo, Valentina Gambardella, Andrés Cervantes, Tania Fleitas-Kanonnikoff, Angela Lamarca
Published 2019-06-01

Personalized Medicine: Recent Progress in Cancer Therapy

by Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Pasquale Lombardi, Marisol Huerta, Susana Roselló, Tania Fleitas, Desamparados Roda, Andres Cervantes
Published 2020-04-01

Immunological Landscape of HER-2 Positive Breast Cancer

by Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo
Published 2022-06-01

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker

by Sara S Oltra, Maria Peña-Chilet, Maria T Martinez, Eduardo Tormo, Juan Miguel Cejalvo, Joan Climent, Pilar Eroles, Ana Lluch, Gloria Ribas
Published 2020-11-01

Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer.

by Denis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, Maurizio Ceppi, Ian James, Max Hasmann, John Crown, Andrés Cervantes, Martin Weisser, Birgit Bossenmaier
Published 2017-01-01

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

by Sonia Pernas, Sonia Pernas, Patricia Villagrasa, Ana Vivancos, Maurizio Scaltriti, Jordi Rodón, Jordi Rodón, Octavio Burgués, Paolo Nuciforo, Jordi Canes, Laia Paré, Marta Dueñas, Marta Dueñas, Maria Vidal, Maria Vidal, Maria Vidal, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Antonia Perelló, Antonio Llommbard-Cussac, Joan Dorca, Alvaro Montaño, Tomás Pascual, Mafalda Oliveira, Mafalda Oliveira, Gloria Ribas, Gloria Ribas, Inmaculada Rapado, Aleix Prat, Aleix Prat, Aleix Prat, Aleix Prat, Eva Ciruelos, Eva Ciruelos
Published 2021-11-01

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

by Cristina Hernando, Belén Ortega-Morillo, Marta Tapia, Santiago Moragón, María Teresa Martínez, Pilar Eroles, Iris Garrido-Cano, Anna Adam-Artigues, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo
Published 2021-07-01

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer

by Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
Published 2023-02-01

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer

by Iris Garrido-Cano, Vera Constâncio, Anna Adam-Artigues, Ana Lameirinhas, Soraya Simón, Belen Ortega, María Teresa Martínez, Cristina Hernando, Begoña Bermejo, Ana Lluch, Paula Lopes, Rui Henrique, Carmen Jerónimo, Juan Miguel Cejalvo, Pilar Eroles
Published 2020-10-01

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies

by Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Federico Rojo, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Lluch, Begoña Bermejo, Felix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pilar Eroles
Published 2022-12-01

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women

by Sara S. Oltra, Juan Miguel Cejalvo, Eduardo Tormo, Marta Albanell, Ana Ferrer, Marta Nacher, Begoña Bermejo, Cristina Hernando, Isabel Chirivella, Elisa Alonso, Octavio Burgués, Maria Peña-Chilet, Pilar Eroles, Ana Lluch, Gloria Ribas, María Teresa Martinez
Published 2020-02-01

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

by Birlipta Pattanayak, Iris Garrido-Cano, Anna Adam-Artigues, Eduardo Tormo, Eduardo Tormo, Begoña Pineda, Begoña Pineda, Begoña Pineda, Paula Cabello, Elisa Alonso, Elisa Alonso, Begoña Bermejo, Begoña Bermejo, Begoña Bermejo, Cristina Hernando, Cristina Hernando, María Teresa Martínez, María Teresa Martínez, Ana Rovira, Ana Rovira, Joan Albanell, Joan Albanell, Joan Albanell, Federico Rojo, Federico Rojo, Octavio Burgués, Octavio Burgués, Juan Miguel Cejalvo, Juan Miguel Cejalvo, Ana Lluch, Ana Lluch, Ana Lluch, Ana Lluch, Pilar Eroles, Pilar Eroles, Pilar Eroles
Published 2020-09-01

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small...

by Enriqueta Felip, Juan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, Alejandro Navarro Mendivil, Maria Martinez Garcia, Alvaro Taus Garcia, Natasha Leighl, Ulrik Lassen, Morten Mau-Soerensen, Celine Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser
Published 2019-07-01

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

by Paula Cabello, Sandra Torres-Ruiz, Anna Adam-Artigues, Jaume Forés-Martos, María Teresa Martínez, Cristina Hernando, Sandra Zazo, Juan Madoz-Gúrpide, Ana Rovira, Octavio Burgués, Federico Rojo, Joan Albanell, Ana Lluch, Begoña Bermejo, Juan Miguel Cejalvo, Pilar Eroles
Published 2023-04-01

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

by Anna Adam-Artigues, Iris Garrido-Cano, Juan Antonio Carbonell-Asins, Ana Lameirinhas, Soraya Simón, Belén Ortega-Morillo, María Teresa Martínez, Cristina Hernando, Vera Constâncio, Octavio Burgues, Begoña Bermejo, Rui Henrique, Ana Lluch, Carmen Jerónimo, Pilar Eroles, Juan Miguel Cejalvo
Published 2021-06-01

NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

by Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba, Miguel López-Botet, Federico Rojo, Ana Rovira, Joan Albanell, Aura Muntasell
Published 2024-01-01

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

by Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Published 2023-04-01